Search for: "AstraZeneca Pharmaceuticals, LP" Results 21 - 40 of 98
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Jul 2007, 9:07 pm
Astrazeneca Pharmaceuticals LP et. al. v. [read post]
23 Nov 2010, 1:00 am by Jason Rantanen
By Jason Rantanen In an earlier post, I summarized the Federal Circuit's affirmance of a preliminary injunction prohibiting Apotex from marketing its generic version of AstraZeneca's budesonide in AstraZeneca LP v. [read post]
10 Mar 2010, 6:05 am by John J. Cord
AstraZeneca Pharmaceuticals LP is now focusing on the drug manufacturer’s advertising strategy. [read post]
8 Dec 2016, 2:00 am by Linda O'Brien
Linda O'BrienCCHPurchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. [read post]
12 May 2017, 9:05 am by Tom Lamb
., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. [read post]
19 Mar 2010, 10:31 am by Dr. Shezad Malik
AstraZeneca Pharmaceuticals LP, MID L 1099 07 MT, Superior Court of New Jersey, Law Division, Middlesex County (New Brunswick). [read post]
13 Nov 2013, 9:14 pm by Patent Docs
The '834 patent is directed to a sterile, pharmaceutically effective budesonide product, which is used to treat asthma in... [read post]
27 Feb 2012, 3:30 am
AstraZeneca Pharmaceuticals, LP, No. 1:10CV104-SA-JAD, 2010 WL 3951906 (N.D. [read post]
28 Sep 2009, 9:56 pm
Sometimes, Sins of Omission Are Not Inequitable Conduct By Kevin E. [read post]
12 Jun 2008, 4:45 am
Omeprazole is the active ingredient in Prilosec ®, which is marketed by Plaintiffs-Appellants Astrazeneca, AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP (Astrazeneca) for the treatment of gastric and duodenal ulcers, and which acts by inhibiting the production of gastric acid. [read post]
29 Mar 2012, 5:47 am by FDABlog HPM
District Court for the District of Columbia denied AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) Motion for Temporary Restraining Order (Complaint here) seeking to vacate FDA’s March 27, 2012 approval of more than 10 ANDAs for generic versions of AstraZeneca’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets (NDA No. 020639), and to enjoin FDA from granting any further final ANDA approvals for the drug until the court… [read post]
12 Feb 2018, 12:05 pm by Tom Lamb
According to that JPML Transfer Order the Defendants -- AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. -- opposed centralization of approximately 80 Onglyza and Kombiglyze lawsuits into this new MDL: Defendants oppose transfer by arguing that plaintiffs’ allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure – not the various other injuries (congestive heart… [read post]
28 Apr 2010, 7:14 am by Mark Zamora
From the DOJ Press Statement:AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration (FDA), the Departments of Justice and Health and Human Services’ Health Care Fraud Enforcement Action Team (HEAT) announced today. [read post]
29 Apr 2013, 1:35 am by FDABlog HPM
District Court for the District of Columbia granting summary judgment for FDA in a case brought by AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) over the approval of generic versions of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets. [read post]